bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Authors: Read Martin L. , Brookes Katie , Zha Ling , Manivannan Selvambigai , Kim Jana , Kocbiyik Merve , Fletcher Alice , Gorvin Caroline M. , Firth George , Fruhwirth Gilbert O. , Nicola Juan P. , Jhiang Sissy , Ringel Matthew D. , Campbell Moray J. , Sunassee Kavitha , Blower Philip J. , Boelaert Kristien , Nieto Hannah R. , Smith Vicki E. , McCabe Christopher J.
Published: April 2024

Supplementary Figure S2
Supplementary Figure S11 from Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Authors: Read Martin L. , Brookes Katie , Zha Ling , Manivannan Selvambigai , Kim Jana , Kocbiyik Merve , Fletcher Alice , Gorvin Caroline M. , Firth George , Fruhwirth Gilbert O. , Nicola Juan P. , Jhiang Sissy , Ringel Matthew D. , Campbell Moray J. , Sunassee Kavitha , Blower Philip J. , Boelaert Kristien , Nieto Hannah R. , Smith Vicki E. , McCabe Christopher J.
Published: April 2024

Supplementary Figure S11
Supplementary Figure S10 from Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
Authors: Read Martin L. , Brookes Katie , Zha Ling , Manivannan Selvambigai , Kim Jana , Kocbiyik Merve , Fletcher Alice , Gorvin Caroline M. , Firth George , Fruhwirth Gilbert O. , Nicola Juan P. , Jhiang Sissy , Ringel Matthew D. , Campbell Moray J. , Sunassee Kavitha , Blower Philip J. , Boelaert Kristien , Nieto Hannah R. , Smith Vicki E. , McCabe Christopher J.
Published: April 2024

Supplementary Figure S10
Supplementary Table S5 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Authors: Song Yuqin , Jin Zhengming , Li Zhi-Ming , Liu Yanyan , Li Lanfang , He Chuan , Su Hang , Zhou Hui , Li Kunyan , Hao Siguo , Zuo Xuelan , Wu Jianyuan , Li Dengju , Wu Meng , Sun Xiuhua , Qi Junyuan , Cai Zhen , Li Zengjun , Li Yijing , Huang Yanhua , Shen Jie , Xiao Zhenyu , Zhu Jun
Published: April 2024

Supplementary Table S5. TRAEs led to treatment interruption.
Supplementary Table S2 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Authors: Song Yuqin , Jin Zhengming , Li Zhi-Ming , Liu Yanyan , Li Lanfang , He Chuan , Su Hang , Zhou Hui , Li Kunyan , Hao Siguo , Zuo Xuelan , Wu Jianyuan , Li Dengju , Wu Meng , Sun Xiuhua , Qi Junyuan , Cai Zhen , Li Zengjun , Li Yijing , Huang Yanhua , Shen Jie , Xiao Zhenyu , Zhu Jun
Published: April 2024

Supplementary Table S2. Efficacy outcomes in patients who were previously treated with tucidinostat (intention-to-treat set).
Supplementary Table S2 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Table 2. The analysis of the DFO-to-antibody ratio for the D10-L111 by native mass spectrometry
Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Authors: Song Yuqin , Jin Zhengming , Li Zhi-Ming , Liu Yanyan , Li Lanfang , He Chuan , Su Hang , Zhou Hui , Li Kunyan , Hao Siguo , Zuo Xuelan , Wu Jianyuan , Li Dengju , Wu Meng , Sun Xiuhua , Qi Junyuan , Cai Zhen , Li Zengjun , Li Yijing , Huang Yanhua , Shen Jie , Xiao Zhenyu , Zhu Jun
Published: April 2024

Supplementary Table S1. Representativeness of study participants.
Supplementary Figure S7 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 7. Biophysical characterization of the purified L111 antibody. A. Analysis of purified L111 antibody integrity by non-reduced (top) and reduced (bottom) capillary electrophoresis-SDS (CE-SDS) on a Perkin Elmer LabChip GXII Touch HT. The table shows the size and migration times of the non-reduced and reduced antibody samples. B. Size-exclusion chromatography high-performance liquid chromatography (SEC-HPLC) analysis of the purified L111 antibody. The table shows the percentage of monomers and high molecular weight species (HMWS). C. Cation-exchange chromatography of the purified L111 antibody. D. Deconvoluted mass spectrometry spectra of the purified L111 antibody. E and F. Analysis of Fc N-Glycan profiles and major glycans distribution by Hydrophilic interaction liquid chromatography (HILIC)-in combination with fluorescence detection (FLD). F. Table shows the percentage of each N-Glycan in the L111 antibody.
Supplementary Figure S4 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 4. SDS-PAGE of eight unique purified human anti-TIP1 full-length IgGs under non-reducing (A) and reducing conditions (B). A. Intact full-length IgGs are observed above 150 kDa. B. In the reducing condition, heavy chains and light chains are observed at 50 kDa and 25 kDa, respectively.
Supplementary Figure S2 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 2. A. Colony PCR showing the completeness of the WashU II library. B. Western blots for the WashU II phages at different dilutions were developed with an anti-pIII antibody showing the fused scFv with the pIII coat protein of the M13 phage. C. Western blots for the WashU II phages at different dilutions were developed with an anti-Flag antibody showing the full-length scFv on the M13 phage.
Supplementary Figure S13 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 13. A. Schematic representation of the tumor implantation, irradiation, antibody injection, PET imaging and post-PET biodistribution schedule. B and C. The tumor SUV max in H460 tumors (B) and A549 tumors (C) at days 2 and 5 post-injection (n=4).
Supplementary Figure S12 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 12. In vitro characterization of [89Zr]Zr-DFO-L111. A. SDS-PAGE under non-reducing and reducing conditions for the [89Zr]Zr-DFO-L111 developed by autoradiography. Four two-fold dilutions were loaded on the SDS-PAGE gel and developed by autoradiography. B. ELISA assay showing binding affinity of the [89Zr]Zr-DFO-L111 to recombinant TIP1 protein.
Supplementary Figure S11 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 11. Specific uptake of the [89Zr]Zr-DFO-L111 in tumors in vivo. Bar graph showing the uptake of the [89Zr]Zr-DFO-Isotype or [89Zr]Zr-DFO-L111 at days 2 and 5 in nude mice bearing A549 tumors in the hindlimb (n=4). Tumors were irradiated with three doses of 3Gy over 24h, followed by injection with radiolabeled antibodies. Cold anti-TIP1 Ab was injected before injecting the radiolabeled for the blocking study. Bar graphs represent %ID/gm. *P<0.05, **P<0.01
Supplementary Figure S10 from Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library
Authors: Singh Abhay K. , Lewis Calvin D. , Boas Cristian A.W.V. , Diebolder Philipp , Jethva Prashant N. , Rhee Aaron , Song Jong Hee , Goo Young Ah , Li Shunqian , Nickels Michael L. , Liu Yongjian , Rogers Buck E. , Kapoor Vaishali , Hallahan Dennis E.
Published: April 2024

Supplementary Figure 10. A. In vitro stability of [89Zr]Zr-DFO-L111 antibodies that were either freshly conjugated with DFO or thawed from -80°C after DFO conjugation. The stability was assessed in human serum by instant thin-layer chromatography. B. In vitro serum stability of [89Zr]Zr-DFO-L111 antibodies in four different buffers. The stability was assessed in human serum by instant thin layer chromatography.
Supplementary Table S6 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Supplemental Table S6. HPV (+) OPSCC de-escalation trial eligibility criteria
Supplementary Table S5 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Supplementary Table S5. Tumor-informed variant numbers and median VAFs in lymphatic fluid
Supplementary Methods S1 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Supplementary methods found here.
Supplementary Figure S5 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Designing a machine learning model that integrates postoperative lymph and plasma MRD to stratify outcomes
Supplementary Figure S3 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Lymph cf-HPV levels are not significantly impacted by surgical variables
Supplementary Figure S1 from Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Authors: Earland Noah , Semenkovich Nicholas P. , Ramirez Ricardo J. , Gerndt Sophie P. , Harris Peter K. , Gu Zhuosheng , Hearn Andrew I. , Inkman Matthew , Szymanski Jeffrey J. , Whitfield Damion , Wahle Benjamin M. , Xu Zhongping , Chen Kevin , Alahi Irfan , Ni Gabris , Chen Andrew , Winckler Wendy , Zhang Jin , Chaudhuri Aadel A. , Zevallos Jose P.
Published: April 2024

Characterization of lymphatic cfDNA and development of a liquid biopsy assay
Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Authors: Kawazoe Akihito , Yamamoto Noboru , Sugimoto Naotoshi , Kawakami Hisato , Oshima Takashi , Yamaguchi Kensei , Hino Kaori , Hirao Motohiro , Kurokawa Yukinori , Kawakami Takeshi , Tsuda Masahiro , Hara Hiroki , Kaname Shota , Matsuoka Daiko , Otake Yohei , Yasuda Keisuke , Takase Takao , Takashima Shuya , Semba Taro , Muro Kei
Published: April 2024

Supplementary Table S3. Tumor responses as assessed by investigator using RECIST v1.1 by prior gastrectomy or liver metastasis at baseline, and by prior ICI treatment
Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Authors: Kawazoe Akihito , Yamamoto Noboru , Sugimoto Naotoshi , Kawakami Hisato , Oshima Takashi , Yamaguchi Kensei , Hino Kaori , Hirao Motohiro , Kurokawa Yukinori , Kawakami Takeshi , Tsuda Masahiro , Hara Hiroki , Kaname Shota , Matsuoka Daiko , Otake Yohei , Yasuda Keisuke , Takase Takao , Takashima Shuya , Semba Taro , Muro Kei
Published: April 2024

Supplementary Table S1. Patient representativeness
Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Authors: van de Haar Joris , Mankor Joanne M. , Hummelink Karlijn , Monkhorst Kim , Smit Egbert F. , Wessels Lodewyk F.A. , Cuppen Edwin , Aerts Joachim G.J.V. , Voest Emile E.
Published: April 2024

Baseline characteristics of patients in the discovery cohort, stratified by the TMB and STK11/KEAP1/EGFR alteration status.
Supplementary Table S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Authors: van de Haar Joris , Mankor Joanne M. , Hummelink Karlijn , Monkhorst Kim , Smit Egbert F. , Wessels Lodewyk F.A. , Cuppen Edwin , Aerts Joachim G.J.V. , Voest Emile E.
Published: April 2024

STK11, KEAP1 and actionable EGFR alterations in the discovery cohort.
Supplementary Table S1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Authors: Li Jing , Wu Andrew , Kim Seongho
Published: April 2024

Supplementary Table S1. Drug-specific parameters.
Supplementary Methods 1 from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Authors: Li Jing , Wu Andrew , Kim Seongho
Published: April 2024

Supplementary Methods
Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Authors: van de Haar Joris , Mankor Joanne M. , Hummelink Karlijn , Monkhorst Kim , Smit Egbert F. , Wessels Lodewyk F.A. , Cuppen Edwin , Aerts Joachim G.J.V. , Voest Emile E.
Published: April 2024

The cTMB and outcome of ICB monotherapy in the discovery cohort.
Supplementary Table S9 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Table S9.The frequency data of rs3744797.
Supplementary Table S4 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Table S4. The differentially expressed genes between gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Supplementary Figure S3 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Figure S3. G > A rs3744797 affects USP36 m6A level by silicon prediction.
Supplementary Figure S1 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Authors: Guan Shaoxing , Chen Xi , Wei Yuru , Wang Fei , Xie Wen , Chen Youhao , Liang Heng , Zhu Xia , Yang Yunpeng , Fang Wenfeng , Huang Yan , Zhao Hongyun , Zhang Xiaoxu , Liu Shu , Zhuang Wei , Huang Min , Wang Xueding , Zhang Li
Published: April 2024

Figure S1. USP36 expression level predicted response of EGFR-TKIs in EGFR-mutant NSCLC.
Supplementary Table S5 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Authors: Lim-Fat Mary Jane , Iorgulescu J. Bryan , Rahman Rifaquat , Bhave Varun , Muzikansky Alona , Woodward Eleanor , Whorral Sydney , Allen Marie , Touat Mehdi , Li Xiaomei , Xy Gongwen , Patel Jay , Gerstner Elizabeth R. , Kalpathy-Cramer Jayashree , Youssef Gilbert , Chukwueke Ugonma , McFaline-Figueroa J. Ricardo , Nayak Lakshmi , Lee Eudocia Q. , Reardon David A. , Beroukhim Rameen , Huang Raymond Y. , Bi Wenya Linda , Ligon Keith L. , Wen Patrick Y.
Published: April 2024

Supplemental Table 5: Association between genetic alterations and age at diagnosis showing significant genes at a false discovery rate (FDR)<0.2.
Supplementary Table S2 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Authors: Lim-Fat Mary Jane , Iorgulescu J. Bryan , Rahman Rifaquat , Bhave Varun , Muzikansky Alona , Woodward Eleanor , Whorral Sydney , Allen Marie , Touat Mehdi , Li Xiaomei , Xy Gongwen , Patel Jay , Gerstner Elizabeth R. , Kalpathy-Cramer Jayashree , Youssef Gilbert , Chukwueke Ugonma , McFaline-Figueroa J. Ricardo , Nayak Lakshmi , Lee Eudocia Q. , Reardon David A. , Beroukhim Rameen , Huang Raymond Y. , Bi Wenya Linda , Ligon Keith L. , Wen Patrick Y.
Published: April 2024

Supplemental Table 2: Multivariable analyses of clinical factors associated with adverse events* showing significant associations at p<0.05.
Supplementary Table S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Authors: Lim-Fat Mary Jane , Iorgulescu J. Bryan , Rahman Rifaquat , Bhave Varun , Muzikansky Alona , Woodward Eleanor , Whorral Sydney , Allen Marie , Touat Mehdi , Li Xiaomei , Xy Gongwen , Patel Jay , Gerstner Elizabeth R. , Kalpathy-Cramer Jayashree , Youssef Gilbert , Chukwueke Ugonma , McFaline-Figueroa J. Ricardo , Nayak Lakshmi , Lee Eudocia Q. , Reardon David A. , Beroukhim Rameen , Huang Raymond Y. , Bi Wenya Linda , Ligon Keith L. , Wen Patrick Y.
Published: April 2024

Supplemental Table 1: Overall survival associated with adverse events.
Supplementary Table S3 from Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Authors: Roy Chaudhuri Tista , Lin Qingxiang , Stachowiak Ewa K. , Rosario Spencer R. , Spernyak Joseph A. , Ma Wen Wee , Stachowiak Michal K. , Greene Michelle K. , Quinn Gerard P. , McDade Simon S. , Clynes Martin , Scott Christopher J. , Straubinger Robert M.
Published: April 2024

Supplementary Table S3. Genes differentially expressed by sHHi treatment in SHHi-responder PDX #18269
Supplementary Table S2 from FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Authors: Woods Ashley , Norsworthy Kelly J. , Wang Xin , Vallejo Jonathon , Chiu Yuen Chow Edwin , Li Ruo-Jing , Sun Jielin , Charlab Rosane , Jiang Xiling , Pazdur Richard , Theoret Marc R. , de Claro R. Angelo
Published: April 2024

Frequent Laboratory Abnormalities
Supplementary Figure S3 from Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Authors: Roy Chaudhuri Tista , Lin Qingxiang , Stachowiak Ewa K. , Rosario Spencer R. , Spernyak Joseph A. , Ma Wen Wee , Stachowiak Michal K. , Greene Michelle K. , Quinn Gerard P. , McDade Simon S. , Clynes Martin , Scott Christopher J. , Straubinger Robert M.
Published: April 2024

Supplementary Figure S3. SSL deposition in PDXs #18269, #14312, and non-responsive PDX #18254
Supplementary Figure S11 from Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Authors: Roy Chaudhuri Tista , Lin Qingxiang , Stachowiak Ewa K. , Rosario Spencer R. , Spernyak Joseph A. , Ma Wen Wee , Stachowiak Michal K. , Greene Michelle K. , Quinn Gerard P. , McDade Simon S. , Clynes Martin , Scott Christopher J. , Straubinger Robert M.
Published: April 2024

Supplementary Figure S11. Effect of sequential SHHi-FGFRi treatment on PDX #14312 tumor morphology and N-cadherin expression
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Authors: Haddox Candace L. , Nathenson Michael J. , Mazzola Emanuele , Lin Jia-Ren , Baginska Joanna , Nau Allison , Weirather Jason L. , Choy Edwin , Marino-Enriquez Adrian , Morgan Jeffrey A. , Cote Gregory M. , Merriam Priscilla , Wagner Andrew J. , Sorger Peter K. , Santagata Sandro , George Suzanne
Published: April 2024

Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments in liposarcoma and UPS/Other cohorts.
Data from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Authors: Bazinet Alexandre , Desikan Sai Prasad , Li Ziyi , Rodriguez-Sevilla Juan Jose , Venugopal Sangeetha , Urrutia Samuel , Montalban-Bravo Guillermo , Sasaki Koji , Chien Kelly S. , Hammond Danielle , Kanagal-Shamanna Rashmi , Ganan-Gomez Irene , Kadia Tapan M. , Borthakur Gautam , DiNardo Courtney D. , Daver Naval G. , Jabbour Elias J. , Ravandi Farhad , Kantarjian Hagop , Garcia-Manero Guillermo
Published: April 2024

AbstractPurpose:
Hypomethylating agents (HMA) combined with venetoclax are an emerging therapeutic strategy for higher-risk myelodysplastic syndromes (HR-MDS). The cytogenetic and molecular factors associated with outcomes with this combination for HR-MDS are incompletely understood.
Experimental Design:
We pooled patient data from 3 prospective trials evaluating HMA–venetoclax in HR-MDS to study associations between cytogenetic and molecular factors and overall response rate (ORR), overall survival (OS), and event-free survival (EFS). The Kaplan–Meier method was used to estimate time-to-event endpoints. Univariate and multivariate analyses using logistic regression (for ORR) or the Cox proportional hazards model (for OS and EFS) were used to identify associations between clinical, cytogenetic, and molecular factors and outcomes.
Results:
A total of 80 patients (52 HMA-naïve, 28 HMA-failure) were included. ORR was 90% in HMA-naïve and 57% in HMA-failure. Median OS was 28.2 and 8.3 months in HMA-naïve and HMA-failure, respectively. Median EFS was 17.9 and 5.5 months in HMA-naïve and HMA-failure, respectively. In addition, 24/52 (46%) of the HMA-naïve and 3/28 (11%) of the HMA-failure patients proceeded to allogeneic stem cell transplantation (SCT). Factors associated with inferior outcomes were prior HMA failure, complex cytogenetics, trisomy 8, TP53 mutations, and RAS pathway mutations. Mutations in RNA splicing, DNA methylation, and ASXL1 appeared favorable. Blast percentage was not predictive of outcomes.
Conclusions:
Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.
Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Authors: Kawazoe Akihito , Yamamoto Noboru , Sugimoto Naotoshi , Kawakami Hisato , Oshima Takashi , Yamaguchi Kensei , Hino Kaori , Hirao Motohiro , Kurokawa Yukinori , Kawakami Takeshi , Tsuda Masahiro , Hara Hiroki , Kaname Shota , Matsuoka Daiko , Otake Yohei , Yasuda Keisuke , Takase Takao , Takashima Shuya , Semba Taro , Muro Kei
Published: April 2024

AbstractPurpose:
E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer. Study 120, a phase Ib/II open-label study, assessed efficacy and safety of E7389-LF in combination with nivolumab, a programmed cell death (PD)-1 inhibitor. This report focuses on the gastric cancer cohort within the expansion phase.
Patients and Methods:
Eligible patients had unresectable, measurable gastric cancer, progression following a platinum drug plus fluoropyrimidine (1L), and a taxane-containing regimen (2L). The primary objective of the expansion phase was objective response rate, secondary objectives included safety and PFS, and exploratory objectives included overall survival and biomarker evaluation. Patients received E7389-LF 2.1 mg/m2 in combination with nivolumab 360 mg every 3 weeks, both as intravenous infusions. Tumor responses were assessed every 6 weeks by the investigators per RECIST v1.1. Plasma and tumor biomarkers were assessed.
Results:
In the 31 patients who received E7389-LF in combination with nivolumab, the objective response rate was 25.8% [confidence interval (CI), 11.9–44.6]. The median progression-free survival was 2.69 months (95% CI, 1.91–2.99) and median overall survival was 7.85 months (95% CI, 4.47–not estimable). The most common treatment-related TEAE of any grade were neutropenia (77.4%), leukopenia (74.2%), and decreased appetite (51.6%). E7389-LF in combination with nivolumab significantly increased CD8-positive cells at C2D1 (P = 0.039), and six of seven vascular markers and four IFNγ-related markers showed increases from C1D1.
Conclusions:
Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with gastric cancer, and no new safety signals were observed, compared with either monotherapy.
Data from Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Authors: Staniszewska Anna D. , Pilger Domenic , Gill Sonja J. , Jamal Kunzah , Bohin Natacha , Guzzetti Sofia , Gordon Jacob , Hamm Gregory , Mundin Gill , Illuzzi Giuditta , Pike Andy , McWilliams Lisa , Maglennon Gareth , Rose Jonathan , Hawthorne Glen , Cortes Gonzalez Miguel , Halldin Christer , Johnström Peter , Schou Magnus , Critchlow Susan E. , Fawell Stephen , Johannes Jeffrey W. , Leo Elisabetta , Davies Barry R. , Cosulich Sabina , Sarkaria Jann N. , O'Connor Mark J. , Hamerlik Petra
Published: April 2024

AbstractPurpose:
We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models.
Experimental Design:
AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using subcutaneous as well as intracranial mouse xenograft models. Mouse, rat, and monkey were used to assess AZD9574 BBB penetration and rat models were used to evaluate potential hematotoxicity for AZD9574 monotherapy and the TMZ combination.
Results:
AZD9574 demonstrated PARP1-selectivity in fluorescence anisotropy, PARylation, and PARP-DNA trapping assays and in vivo experiments demonstrated BBB penetration. AZD9574 showed potent single agent efficacy in preclinical models with homologous recombination repair deficiency in vitro and in vivo. In an O6-methylguanine-DNA methyltransferase (MGMT)–methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared with TMZ alone.
Conclusions:
The combination of three key features—PARP1 selectivity, PARP1 trapping profile, and high central nervous system penetration in a single molecule—supports the development of AZD9574 as the best-in-class PARP inhibitor for the treatment of primary and secondary brain tumors. As documented by in vitro and in vivo studies, AZD9574 shows robust anticancer efficacy as a single agent as well as in combination with TMZ. AZD9574 is currently in a phase I trial (NCT05417594).

See related commentary by Lynce and Lin, p. 1217
Data from Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System
Authors: Li Jing , Wu Andrew , Kim Seongho
Published: April 2024

AbstractPurpose:
The pharmacokinetics of intrathecally administered antibody or small-molecule drugs in the human central nervous system (CNS) remains poorly understood. This study aimed to provide mechanistic and quantitative perspectives on the CNS pharmacokinetics of intrathecal chemotherapy, by using a physiologically based pharmacokinetic (PBPK) modeling approach.
Experimental Design:
A novel CNS PBPK model platform was developed and verified, which accounted for the human CNS general anatomy and physiologic processes governing drug distribution and disposition. The model was used to predict CNS pharmacokinetics of antibody (trastuzumab) and small-molecule drugs (methotrexate, abemaciclib, tucatinib) following intraventricular injection or intraventricular 24-hour infusion, and to assess the key determinants of drug penetration into the deep brain parenchyma.
Results:
Intraventricularly administered antibody and small-molecule drugs exhibited distinct temporal and spatial distribution and disposition in human CNS. Both antibody and small-molecule drugs achieved supratherapeutic or therapeutic concentrations in the cerebrospinal fluid (CSF) compartments and adjacent brain tissue. While intrathecal small-molecule drugs penetrated the deep brain parenchyma to a negligible extent, intrathecal antibodies may achieve therapeutic concentrations in the deep brain parenchyma. Intraventricular 24-hour infusion enabled prolonged CNS exposure to therapeutically relevant concentrations while avoiding excessively high and potentially neurotoxic drug concentrations.
Conclusions:
CNS PBPK modeling, in line with available clinical efficacy data, confirms the therapeutic value of intrathecal chemotherapy with antibody or small-molecule drugs for treating neoplastic meningitis and warrants further clinical investigation of intrathecal antibody drugs to treat brain parenchyma tumors. Compared with intraventricular injection, intraventricular 24-hour infusion may mitigate neurotoxicity while retaining potential efficacy.
Data from Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Authors: Roy Chaudhuri Tista , Lin Qingxiang , Stachowiak Ewa K. , Rosario Spencer R. , Spernyak Joseph A. , Ma Wen Wee , Stachowiak Michal K. , Greene Michelle K. , Quinn Gerard P. , McDade Simon S. , Clynes Martin , Scott Christopher J. , Straubinger Robert M.
Published: April 2024

AbstractPurpose:
Paracrine activation of pro-fibrotic hedgehog (HH) signaling in pancreatic ductal adenocarcinoma (PDAC) results in stromal amplification that compromises tumor drug delivery, efficacy, and patient survival. Interdiction of HH-mediated tumor-stroma crosstalk with smoothened (SMO) inhibitors (SHHi) “primes” PDAC patient-derived xenograft (PDX) tumors for increased drug delivery by transiently increasing vascular patency/permeability, and thereby macromolecule delivery. However, patient tumor isolates vary in their responsiveness, and responders show co-induction of epithelial–mesenchymal transition (EMT). We aimed to identify the signal derangements responsible for EMT induction and reverse them and devise approaches to stratify SHHi-responsive tumors noninvasively based on clinically-quantifiable parameters.
Experimental Design:
Animals underwent diffusion-weighted magnetic resonance (DW-MR) imaging for measurement of intratumor diffusivity. In parallel, tissue-level deposition of nanoparticle probes was quantified as a marker of vascular permeability/perfusion. Transcriptomic and bioinformatic analysis was employed to investigate SHHi-induced gene reprogramming and identify key “nodes” responsible for EMT induction.
Results:
Multiple patient tumor isolates responded to short-term SHH inhibitor exposure with increased vascular patency and permeability, with proportionate increases in tumor diffusivity. Nonresponding PDXs did not. SHHi-treated tumors showed elevated FGF drive and distinctly higher nuclear localization of fibroblast growth factor receptor (FGFR1) in EMT-polarized tumor cells. Pan-FGFR inhibitor NVP-BGJ398 (Infigratinib) reversed the SHHi-induced EMT marker expression and nuclear FGFR1 accumulation without compromising the enhanced permeability effect.
Conclusions:
This dual-hit strategy of SMO and FGFR inhibition provides a clinically-translatable approach to compromise the profound impermeability of PDAC tumors. Furthermore, clinical deployment of DW-MR imaging could fulfill the essential clinical–translational requirement for patient stratification.
Infancias, Subjetividades y Experiencias de Participación. Narrativas de Niñas y Niños de El Salvador, Perú y Colombia
Authors: Rodríguez Castrillón Claudia María
Published: April 2024

Se presenta en este artículo, a manera de estado del arte, la producción de conocimiento en los últimos 17 años en torno a la participación de los niños y las niñas. Para ello, se revisaron diversos estudios y, desde su interpretación, se realizó una clasificación en tres tendencias que recogen conceptos como participación infantil, ciudadanías, sujetos de derecho y protagonismo infantil. Teóricamente, la reflexión se alimenta de las posturas de autores como Michel Foucault, Manfred Liebel, Alejandro Cussiánovich, Iván Rodríguez, Berry Mayall. Se propone reflexionar sobre la importancia de trascender la mirada de los niños y las niñas como sujetos “depositarios” de derechos, desde la enunciación y observación de los adultos, para reivindicar desde otras apuestas comprensivas la participación como experiencia y las subjetividades que allí emergen.
A expressão tectônica da arquitetura vernácula: o caso de Lapinha da Serra (MG)
Authors: Oliveira Caroline Santos de , Vimieiro Jhade Iane Cunha , Castro Maria Luiza Almeida Cunha de
Published: April 2024

The architecture historiography and analysis dedicated itself to the great erudite and monumental architectural works, especially to modern architecture. This also happened with the analysis from the perspective of tectonics. In this scenario, vernacular architecture was placed on the sidelines of critical architecture analysis, especially under the tectonic approach. Therefore, in this work, it sought to elucidate the systematic movements that vernacular architecture presents with the concept of tectonic. Thus, a case study of a vernacular adobe residence located in Lapinha da Serra, district of Santana do Riacho (MG) was carried out, the case study evidenced the omnipresent character of tectonics in vernacular architecture.
Ferrovias, desenvolvimento urbano e questões do patrimônio no Brasil: o caso de Patos-PB
Authors: Campos Cristina de , Almeida Eneida de , Almeida Bruno Fontes
Published: April 2024

O objetivo é discorrer sobre o desenvolvimento econômico, social e urbano de Patos-PB no decorrer da instalação da linha férrea na cidade. Nas primeiras décadas do século XX, Patos ocupou posição destacada dentro da economia regional, tendo sua industrialização atrelada à cultura do algodão, tornando-se atraente para instalação da ferrovia. O trabalho aborda essa história e suas interfaces com o desenvolvimento urbano, por meio de uma linha cronológica das principais transformações e seu impacto para a população, para refletir sobre o patrimônio e sua combinação com as pautas urbanas. Percebe-se com este estudo que a desvalorização e a degradação das estruturas ferroviárias contribuem, de certo modo, para a desconexão entre os remanescentes do passado e o tecido urbano do presente. Desconexão essa que poderia ser contraposta favorecendo a interação e engajamento dos diferentes atores sociais tanto nos processos de planejamento, quanto na formulação das políticas de preservação do patrimônio cultural.
Norman Foster: uma exposição retrospectiva
Authors: Zanardi José Eduardo
Published: April 2024

Sin resumen
Long-legged flies (Diptera: Dolichopodidae) in the Czech Republic—2. Corindia and Thrypticus
Authors: KEJVAL ZBYNĚK , POLLET MARC
Published: April 2024

The faunistics of long-legged flies of the genera Corindia Bickel, 1986 and Thrypticus Gerstäcker, 1864 in the Czech Republic (subdivided into Bohemia and Moravia) were investigated. The occurrence of 14 species could be confirmed with 13 in Thrypticus, including Thrypticus bolevensis sp. nov., and one species of Corindia. Six species are recorded from the Czech Republic for the first time: Thrypticus cynicus Drake & Godfrey, 2023, T. intercedens Negrobov, 1967, T. nigricauda Wood, 1913, T. pollinosus Verrall, 1912, T. tarsalis Parent, 1932 and T. virescens Negrobov, 1967; and three other species from Bohemia for the first time: Corindia viridis (Parent, 1932), Thrypticus cuneatus (Becker, 1917) and T. laetus Verrall, 1912. An updated checklist of Corindia and Thrypticus species of the Czech Republic is provided.
A new species of the genus Caprella Lamarck, 1801 (Crustacea, Amphipoda, Caprellidae) from Korea
Authors: HEO JUN-HAENG , SHIN SO-YEON , KIM YOUNG-HYO
Published: April 2024

A new species of the genus Caprella, belonging to the family Caprellidae, has been collected from the East Sea of Korea. The new species, Caprella megabranchia sp. nov., is morphologically similar to C. brevirostris Mayer, 1903, in terms of the shape of the propodus of gnathopod 2 and pereopods 5–7, propodi lacking grasping robust seta. However, the new species can be easily distinguished from C. brevirostris by its entirely circular gills and the anterior convexity of peduncular article 3 in antenna 1. The new species is illustrated and compared to related species C. brevirostris and a key to the Caprella species in Korea is also provided.
Simulated Warming Hole in Paleo-Pacific Oceans
Authors: Wei Mengyu , Yang Jun , Hu Yongyun , Liu Yonggang , Hu Shineng , Li Xiang , Lan Jiawenjing , Guo Jiaqi , Yuan Shuai , Nie Ji
Published: April 2024

Both observations and simulations show that under global warming, there exists a warming deficit in the North Atlantic, known as the North Atlantic warming hole (NAWH). Here, we show that a similar warming hole occurs in the subpolar Pacific Ocean of paleoclimate simulations. As the solar constant is increased, the local surface becomes substantially cooler rather than warmer in the subpolar paleo-Pacific Ocean under the land–sea configurations of 70, 90, and 150 million years ago (Ma). The warming hole has a magnitude of ≈3°C and is located in the Northern Hemisphere in 70 and 90 Ma. The warming hole in 150 Ma has a magnitude of ≈1°C and is located in the Southern Hemisphere. Both atmospheric and oceanic processes contribute to trigger the warming hole. For 70- and 90-Ma experiments, atmospheric teleconnection along a great circle from tropics to extratropics intensifies surface winds over subpolar ocean and thereby increases relatively cool seawater transport from high to low latitudes. Meanwhile, global meridional overturning circulation (GMOC) becomes weaker, causing a divergence of the meridional ocean heat transport in the warming hole region. An increasing regional cloud shortwave cooling effect acts to further enhance the warming hole. For 150-Ma experiments, the warming hole is related to the meridional shift of midlatitude jet stream and the weakening of GMOC in the Southern Hemisphere. The strength and phase of the atmospheric teleconnection and the response of GMOC strongly depend on land–sea configuration, resulting in the paleo-Pacific warming hole to occur in special periods only.
Chest Tube Size Selection: Evaluating Provider Practices, Treatment Efficacy, and Complications in Management of Thoracic Trauma
Authors: Messa Genevieve E. , Fontenot Cameron J. , Deville Paige E. , Hunt John P. , Marr Alan B. , Schoen Jonathan E. , Stuke Lance E. , Greiffenstein Patrick P. , Smith Alison A.
Published: April 2024

Background

The standard for managing traumatic pneumothorax (PTX), hemothorax (HTX), and hemopneumothorax (HPTX) has historically been large-bore (LB) chest tubes (>20-Fr). Previous studies have shown equal efficacy of small-bore (SB) chest tubes (≤19-Fr) in draining PTX and HTX/HPTX. This study aimed to evaluate provider practice patterns, treatment efficacy, and complications related to the selection of chest tube sizes for patients with thoracic trauma.

Methods

A retrospective chart review was performed on adult patients who underwent tube thoracostomy for traumatic PTX, HTX, or HPTX at a Level 1 Trauma Center from January 2016 to December 2021. Comparison was made between SB and LB thoracostomy tubes. The primary outcome was indication for chest tube placement based on injury pattern. Secondary outcomes included retained hemothorax, insertion-related complications, and duration of chest tube placement. Univariate and multivariate analyses were performed.

Results

Three hundred and forty-one patients were included and 297 (87.1%) received LB tubes. No significant differences were found between the groups concerning tube failure and insertion-related complications. LB tubes were more frequently placed in patients with penetrating MOI, higher average ISS, and higher average thoracic AIS. Patients who received LB chest tubes experienced a higher incidence of retained HTX.

Discussion

In patients with thoracic trauma, both SB and LB chest tubes may be used for treatment. SB tubes are typically placed in nonemergent situations, and there is apparent provider bias for LB tubes. A future randomized clinical trial is needed to provide additional data on the usage of SB tubes in emergent situations.
Near-Infrared Fluorescent Probe for the Detection of Cysteine
Authors: Wang Minghui , Yang Xindi , Yuan Mengyao , Zhou Wei , Yang Li
Published: April 2024

Hemicyanine dyes are an ideal structure for building near-infrared fluorescent probes due to their excellent emission wavelength properties and biocompatibility in biological imaging field. Developing a near-infrared fluorescent probe capable of detecting cysteine (Cys) was the aim of this study. A novel developed fluorescent probe P showed high selectivity and sensitivity to Cys in the presence of various analytes. The detection limit of P was found to be 0.329 μM. The MTT assay showed that the probe was essentially non-cytotoxic. Furthermore, the probe was successfully used as cysteine imaging in living cells and mice.
More Than One Way to Pivot: The Case for Opportunity and Survival Pivots
Authors: Allen Jared S. , Combs James G. , Carr Jon C. , Michaelis Timothy L. , Joseph Dana L.
Published: April 2024

Research describes pivots as quick and comprehensive change in venture direction triggered by (external) opportunity-based information suggesting a better opportunity. We discovered two distinct pivot types in a qualitative study (Study 1), neither of which fully aligns with prior research. “Opportunity pivots” are triggered by opportunity-based information but are slower and less comprehensive than previously described; “survival pivots” are rapid and comprehensive but triggered by (internal) threat-based information. Lacking theory to explain our discoveries, we tested competing theories in an experimental vignette study involving 1,945 entrepreneurs (Study 2). We find that entrepreneurial learning explains opportunity but not survival pivots, and prospect theory explains survival but not opportunity pivots. The discovery of distinct pivot types provides a foundation for exploring additional pivoting variation; finding support for a different theoretical explanation for each pivot type suggests important limits to core theories used to explain pivoting.
Couples’ empathy and sensitive responsiveness to a crying baby simulator
Authors: Kaźmierczak Maria , Pawlicka Paulina , Anikiej-Wiczenbach Paulina , Łada-Maśko Ariadna , van IJzendoorn Marinus H. , Bakermans-Kranenburg Marian J.
Published: April 2024

Emotional empathy has been linked to prosocial behaviors and is deemed crucial for parenting and caring for infants. This study examined whether emotional empathy (dispositional and in response to infant crying) is associated with sensitive responsiveness, as observed in 221 heterosexual couples (half of whom were expecting their first child) during a standardized caregiving situation. Simulators resembling real infants were used. Caregiving performed by each partner individually and as a couple was observed using the Ainsworth sensitivity scale. The partners rated their own empathy and their perceived partner’s empathy toward the infant simulator. The Polish version of the Interpersonal Reactivity Index was used to measure dispositional emotional empathy (empathic concern, EC; personal distress, PD). Multilevel modeling showed that self-reported and partner-reported empathy elicited by the infant simulator mediated the association between dispositional empathic concern and sensitive responsiveness during caretaking. Women were more empathic and responsive while caring for the infant simulator, and couple sensitive responsiveness was predicted by higher dispositional EC and lower PD in women but not in men. Our findings suggest that dispositional empathy and empathic reactions toward an infant simulator might translate into better adjustment to parenthood and more responsive parenting and coparenting.
Mechanical properties of CO2 laser beam butt-welded plates of Hastelloy c-276
Authors: Vemanaboina Harinadh , Kunduru Krishnamohan Reddy , Kumar Panchagnula Kishore , Goud R Raman , Gowd G Harinath
Published: April 2024

In the current investigation, thermo-mechanical analysis is carried out for Hastelloy C-276 using laser beam welded butt joints. The Gaussian heat source model is used for transient thermal analysis, and the maximum temperature at the weld area resulted in residual stresses within safe limits. To validate, the experimentation was carried out with CO2 Laser beam welding using an L4 orthogonal array. Sample 2 had the least-residual stresses in the weldment, and the mechanical and metallurgical properties studies were carried out. The residual stress distribution was measured using X-ray diffraction and was acceptable within the yield limits of the material. Finite Element Analysis (FEA) and experimental residual stresses were compared; the FOS was 2.088, and the remaining samples were more than 2.0 compared to the base material tensile strength. Tensile tests confirmed that the strength of the weld zone is higher than that of the parent metals.